Noven will keep its name and remain at its current New York and Miami locations with its existing staff after its purchase by Hisamitsu Pharmaceutical Co. Hisamitsu will buy Noven for $16.50 per share which is a 22.4 percent premium on Noven stock"s most recent closing price.